226 related articles for article (PubMed ID: 23865680)
1. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
3. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
4. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
Kayık G; Tüzün NŞ; Durdagi S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of phosphodiesterase 6 response on binding catalytic site inhibitors.
Simon A; Barabás P; Kardos J
Neurochem Int; 2006 Aug; 49(3):215-22. PubMed ID: 16519963
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
8. Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Li Y; Wu W; Ren H; Wang J; Zhang S; Li G; Yang L
J Mol Graph Model; 2012 Sep; 38():112-22. PubMed ID: 23085160
[TBL] [Abstract][Full Text] [Related]
9. Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.
Ceyhan O; Birsoy K; Hoffman CS
Chem Biol; 2012 Jan; 19(1):155-63. PubMed ID: 22284362
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
[TBL] [Abstract][Full Text] [Related]
11. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
12. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
Hamza A; Zhan CG
J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
14. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
Lau JK; Li XB; Cheng YK
J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
[TBL] [Abstract][Full Text] [Related]
15. Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei.
Rascón A; Soderling SH; Schaefer JB; Beavo JA
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4714-9. PubMed ID: 11930017
[TBL] [Abstract][Full Text] [Related]
16. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
Wang Y; Ke H
Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
Huai Q; Liu Y; Francis SH; Corbin JD; Ke H
J Biol Chem; 2004 Mar; 279(13):13095-101. PubMed ID: 14668322
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the activity of drugs that inhibit phosphodiesterases.
Card GL; England BP; Suzuki Y; Fong D; Powell B; Lee B; Luu C; Tabrizizad M; Gillette S; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Structure; 2004 Dec; 12(12):2233-47. PubMed ID: 15576036
[TBL] [Abstract][Full Text] [Related]
19. Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
Weeks JL; Corbin JD; Francis SH
J Pharmacol Exp Ther; 2009 Oct; 331(1):133-41. PubMed ID: 19641165
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 11: a brief review of structure, expression and function.
Makhlouf A; Kshirsagar A; Niederberger C
Int J Impot Res; 2006; 18(6):501-9. PubMed ID: 16395323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
